SOUTH SAN FRANCISCO, Calif. , Aug. 20, 2024 /PRNewswire/ -- Human Longevity, Inc.
(HLI), with over 10 years as a longevity focused technology company, today announced the completion of an oversubscribed $39.8M Series B round led by TVM Capital Healthcare with participation from new and existing investors, including Panacea Venture and Emerging Technology Partners. The funding will be used to invest in HLI's artificial intelligence health risk and recommendation platform, new longevity focused technologies and services, and new expansion sites globally.
Founded in 2013, with a group of pioneers in the precision medicine field, HLI has made significant research and development progress in the longevity field. In 2020, the company published groundbreaking research in the Proceedings of the National Academy of Sciences, demonstrating the integration of whole-genome sequencing, comprehensive metabolomics, and advanced imaging to identify significant health risk. As result of our research, we have created a 100+ Longevity care membership program to identify early stages of the major age-related health diseases, with the goal to increase healthspan and extend lifespan through the company's clinical care team and data platform.
The 100+ Longevity Care program leverages precision medicine health data, clinical care, targeted interventions and the program also focuses on reducing biological age. Key components include whole genome sequencing, whole-body and brain MRI, comprehensive car.